New members include acclaimed genetic counselors Jill Davies, M.S., CCGC, director of genetics and genomics at Medcan Clinic, and Elissa Levin, M.S., CGC, assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai

 

 MedMtSinai

 

Pathway Genomics has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.

“Collaborating with expert genetic counselors is a critical part of Pathway’s dedication to providing clinical genetic information to patients and their physicians. Part of that dedication is to help patients learn about their genetic results through a genetic counselor.”

Linda Wasserman, M.D., Ph.D.
Laboratory Director, Pathway Genomics
Former Director of the Clinical Cancer
Genetics Care Unit, UC San Diego Moores Cancer Center

With more than 10 years as a genetic counselor, Jill Davies, M.S., CCGC, is the current director of genetics and genomics at Medcan Clinic, where she has developed a leading-edge genetics program with a range of services. Her special interest is in the role of genetics in primary care and preventive medicine, focusing on bringing the most advanced genetics knowledge to individuals to help them optimize health and manage risk for disease. As the co-investigator on the Personal Genome Project Canada (PGPC), in 2012 she became the first Canadian to have her whole genome sequenced as part of this project. Davies is an active member of the Ontario Personalized Medicine Network, the National Society of Genetic Counselors and is a Canadian board-certified genetic counselor.

Elissa Levin, M.S., CGC, is the head of Genomics and Integrative Health Innovations and assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. Previously she was at Life Technologies, where she developed and led the clinical support services department, providing clinical genomics expertise to the global organization. Levin began her career working in academic medical centers where she provided clinical genetic counseling for the Division of General and Metabolic Genetics at the University of California San Francisco and coordinated a multicenter, NIH-funded trial on the genetic basis of congenital heart disease at the Children’s Hospital of Philadelphia.

Pathway Genomics’ advisory board consists of leaders in various fields including genetic counseling, oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full advisory board, visit www.pathway.com.

Pathway Genomics today announced that Nature Genetics founding editor Kevin Davies, Ph.D., has joined its scientific advisory board.

“I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

Kevin Davies, Ph.D.
Author of The $1,000 Genome and Cracking the Genome
Founding Editor, Nature Genetics

“I have followed Pathway closely for many years, reporting on the launch of the company in my book, The $1,000 Genome,” said Davies. “I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

A highly respected science journalist, editor, and publisher with more than 20 years of experience at the forefront of advances in genetics and medicine, Davies is currently a vice president with the American Chemical Society, the largest scientific society in the world, where he serves as publisher of Chemical & Engineering News, the society’s weekly magazine. He has also served as editor-in-chief for Cell Press and was the founding editor of Bio-IT World magazine.

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,”

Ardy Arianpour
Chief Strategy Officer
Pathway Genomics

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We are exceptionally pleased to collaborate with an opinion leader of his status.”

Born in London, Davies studied biochemistry and molecular genetics at the Universities of Oxford and London before moving to the United States. He conducted postdoctoral fellowships at MIT and Harvard Medical School before moving into science publishing. Davies is the author of three popular-science books on the medical and societal implications of the genomics revolution, including Cracking the Genome and most recently The $1,000 Genome. He is a sought-after public speaker and an occasional technical consultant to the film industry, most recently serving as genetics consultant for the film Decoding Annie Parker.

Pathway Genomics’ scientific advisory board consists of leaders in various fields including oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full scientific advisory board, visit www.pathway.com.

Pathway Genomics has added Illumina NextSeq 500 systems to its force of NGS sequencers, enhancing the company’s established and highly efficient laboratory processes.

 

The NextSeq 500’s push-button operation provides a one-day turnaround time for an array of popular sequencing applications such as a single human genome, and up to 16 exomes, 20 transcriptomes, 48 gene expression samples, 20 non-invasive prenatal samples, and 96 targeted panels. Additionally, with the sequencer’s streamlined informatics, sequencing data can be run through a range of commercial pipelines.

The NextSeq 500 provides a one-day turnaround time for an array of popular sequencing applications.

Continue reading »

Pathway Genomics announced that world-renowned geneticist George Church, Ph.D., has joined its scientific advisory board. He is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Dr. Church is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Continue reading »

 

Pathway Genomics has added the Illumina MiSeqDx to its fleet of next-generation sequencing systems.

 

 

 

Designed and validated for the clinical market, the benchtop sequencing system will optimize the company’s ability to develop and run diagnostic applications. It enables sample multiplexing, maximizing operator efficiency and increasing throughput.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

Continue reading »

Pathway Genomics today announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test. Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

Continue reading »

Former senior vice president of business development at Ambry Genetics to drive go-to-market strategies for Pathway Genomics

 

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services worldwide, today announced it has appointed Ardy Arianpour, MBA, as chief strategy officer. Based at Pathway Genomics’ San Diego headquarters, in this executive management position, Arianpour will spearhead the company’s global strategy, strategic planning, and lucrative partnerships for the company.

“Ardy is an industry expert and a highly respected leader with a wealth of deep experience in the biotechnology and personalized genomics space,” said Jim Plante, Pathway Genomics’ founder and CEO.

“Ardy is an industry expert and a highly respected leader with a wealth of deep experience in the biotechnology and personalized genomics space,” said Jim Plante, Pathway Genomics’ founder and CEO.

Continue reading »

The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

This month, Pathway Genomics’ founder and CEO, Jim Plante, attended an exclusive dinner event with President Barack Obama. The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

“By offering a comprehensive cancer panel, we are doing our part in helping to reduce the number of cancer victims across the nation – and around the world,” said Plante.

Continue reading »


As one of the sponsors of the event, Pathway Genomics participated in the 2013 Komen San Diego Race for the Cure® 5K.

As one of the sponsors of the event, Pathway Genomics participated in the 2013 Komen San Diego Race for the Cure® 5K.

Susan G. Komen for the Cure is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. The Race for the Cure series raises significant funds and awareness for the breast cancer movement.

Continue reading »

Pathway Genomics Corporation, a San Diego-based CAP-accredited clinical laboratory that offers genetic testing services worldwide, today announced it has received a Clinical Laboratory Permit from the New York State Department of Health. The permit allows authorized health care providers in the state of New York the ability to offer their patients Pathway Fit®, the company’s diet, metabolism, and exercise genetic test.

Considered one of the most rigorous control standards in the country, the validation process required for a New York State Clinical Laboratory Permit is designed to ensure reliable, accurate clinical laboratory services. “Obtaining a New York State Clinical Laboratory Permit is an exciting benchmark in Pathway’s growth and a testament to the quality, reliability and accuracy of Pathway’s services,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer.

Continue reading »